Clinical Trials Browser

Phase 1/2 × Part 1：r/r B-cell Malignancies × orelabrutinib × Clear all

NCT04014205 2023-04-18

A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

Phase 1/2 Unknown

Part 1：r/r B-cell Malignancies